Effect of high-dose intravenous immunoglobulin treatment in therapy-resistant chronic spontaneous urticaria

Annals of Allergy, Asthma and Immunology

Volumn 104, Issue 3, 2010, Pages 253-258

  Mitzel Kaoukhov, Heidrun ^a   Staubach, Petra ^a   Müller Brenne, Tina ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; CORTICOSTEROID; CORTISONE; CYCLOSPORIN; DAPSONE; IMMUNOGLOBULIN; PARACETAMOL; PSORALEN;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC SPONTANEOUS URTICARIA; CHRONIC URTICARIA; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; ECZEMA; EDEMA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; IMMUNOTHERAPY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PRURITUS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; FEMALE; HEADACHE; HUMANS; HYPERTENSION; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URTICARIA;

EID: 77649173981     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2009.12.007     Document Type: Article

References (19)

1. Staubach P., Eckhardt-Henn A., Dechene M., et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 154 (2006) 294-298
2. 2LEN/EDF/WAO guideline: definition, classification, and diagnosis of urticaria. Allergy 64 (2009) 1417-1426
3. O'Donnell B.F., Barr R.M., Black A.K., et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 138 (1998) 101-106
4. Imbach P., Barandun S., d'Apuzzo V., et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1 (1981) 1228-1231
5. Hartung P. Advances in the understanding of mechanism of action of IVIG. J Neurol 255 (2008) 3-6
6. Mlynek A., Zalewska-Janowska A., Martus P., Staubach P., Zuberbier T., and Maurer M. How to assess disease activity in patients with chronic urticaria?. Allergy 63 (2008) 777-780
7. Greaves M.W. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 3 (2003) 363-368
8. Staubach P., Onnen K., Vonend A., et al. Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial. Dermatology 212 (2006) 150-159
9. Dawn G., Urcelay M., Ah-Weng A., O'Neill S.M., and Douglas W.S. Effect of high-dose intravenous immunoglobulin in delayed pressure urticaria. Br J Dermatol 149 (2003) 836-840
10. Klote M.M., Nelson M.R., and Engler R.J. Autoimmune urticaria response to high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 94 (2005) 307-308
11. Puech-Plottova I., Michel J.L., Rouchouse B., Perrot J.L., Dzviga C., and Cambazard F. Solar urticaria: one case treated by intravenous immunoglobulin. Ann Dermatol Venereol 127 (2000) 831-835
12. Darras S., Segard M., Mortier L., Bonnevalle A., and Thomas P. Treatment of solar urticaria by intravenous immunoglobulins and PUVA therapy. Ann Dermatol Venereol 131 (2004) 65-69
13. Correia I., Silva J., Filipe P., and Gomes M. Solar urticaria treated successfully with intravenous high-dose immunoglobulin: a case report. Photodermatol Photoimmunol Photomed 24 (2008) 330-331
14. Asero R. Are IVIG for chronic unremitting urticaria effective?. Allergy 55 (2000) 1099-1101
15. Staubach-Renz P., von Stebut E., Bräuninger W., Maurer M., and Steinbrink K. Hypokomplementämisches Urtikaria-Vaskulitis-Syndrom. Hautarzt 58 (2007) 693-697
16. Rütter A., and Luger T. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. Am Acad Dermatol 44 (2001) 1010-1024
17. Metz M., Bergmann P., Zuberbier T., and Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 63 (2008) 247-249
18. Spector S.L., and Tan R.A. Advances in allergic skin disease: omalizumab is a promising therapy for urticaria and angioedema. J Allergy Clin Immunol 123 (2009) 273-274
19. Callejas-Rubio J.L., Sanchez-Cano D., Lara M.A., and Ortego-Centeno N. Omalizumab as a therapeutic alternative for chronic urticaria. Ann Allergy Asthma Immunol 101 (2008) 556